Medarex, Inc. Announces Extension of Broad Antibody Development Relationship with Centocor, Inc.
PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. today announced the extension of a broad antibody development relationship with its licensing partner, Centocor R&D, Inc. The extended relationship provides Centocor with continued access to Medarex's UltiMAb Human Antibody Development System(R) for the generation of fully human antibodies to an unlimited number of targets.
Under the terms of the new agreement, Centocor will license Medarex's UltiMAb(R) technology to discover and potentially develop and commercialize fully human antibody therapeutics. Medarex expects to receive license fees and milestone payments as well as royalties on commercial sales of any products that may result from this agreement. No further financial terms of the agreement were disclosed.
Centocor first licensed the UltiMAb technology in 1997, and an expanded agreement was announced in 2000.
"We are delighted with the opportunity to continue our relationship with Centocor," said Howard H. Pien, President and CEO of Medarex. "We have been pleased to be a partner to Centocor in its development of UltiMAb antibodies into potentially very important products, and we look forward to the extension of this partnership into the future."
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, uncertainties concerning Centocor's activities under its agreement with Medarex, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.Medarex, Inc.
CONTACT: Laura S. Choi, Investor Relations, x2216, or Jean Mantuano,Corporate Communications, media, x2221, both of Medarex, Inc., +1-609-430-2880
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html /